Real-World Evidence Submissions to the Center for Biologics Evaluation and Research & the Center for Drug Evaluation and Research

As part of the reauthorization of the Prescription Drug User Fee Act (PDUFA VII), FDA committed to reporting aggregate and anonymized information on submissions to the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER).

Recommend0 recommendationsPublished in US National Health Agency Sources

Related Articles

FDA’s Big Plan to Enhance Public Health in 2025

The Food and Drug Administration (FDA) recently announced its request for $7.2 billion as part of President Joe Biden’s fiscal year (FY) 2025 proposed budget. FDA’s request, which is about 7% higher than last year, covers the agency’s top health priorities. “This funding will allow the agency to enhance food safety and nutrition, advance medical …
The post FDA’s Big Plan to Enhance Public Health in 2025 appeared first on Salud America.

As Social Need Screening Advances, Transportation Remains an Afterthought

Some big changes in 2022 and 2023 have set up the healthcare sector to advance screening for non-medical social needs in 2024 and beyond. This is great news as we work to address social determinants of health (SDoH), improve health outcomes, and reduce health disparities. But one key social need – transportation – isn’t getting …
The post As Social Need Screening Advances, Transportation Remains an Afterthought appeared first on Salud America.